<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203212</url>
  </required_header>
  <id_info>
    <org_study_id>Menomyobone</org_study_id>
    <nct_id>NCT04203212</nct_id>
  </id_info>
  <brief_title>BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH</brief_title>
  <official_title>Bone Mineral Density Alterations and Correlations With Bone and Muscle Metabolism Parameters During Menstrual Cessation Due to GnRH Therapy and After Menstrual Restoration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>424 General Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>251 Hellenic Air Force &amp; VA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>424 General Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effect of menstrual cessation in women with
      endometriosis treated with GnRH analogs for 6 months on bone mineral density and bone and
      muscle metabolism parameters and subsequently the effects of menstrual restoration after GnRH
      analogs discontinuation on the above measured parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-label, controlled 12month observational study

      Premenopausal women with surgically verified endometriosis will receive goserelin 1 injection
      per month for 6 months. Subsequently goserelin will be discontinued and patients will be
      monitored for another 6 months after menstrual restoration. Age- and BMI-matched
      premenopausal, health women will serve as controls. Controls will receive no treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>lumbar spine BMD</measure>
    <time_frame>between baseline and 6 months after goserelin initiation</time_frame>
    <description>Bone mineral density changes at the lumbar spine measured by dual-energy absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lumbar spine BMD</measure>
    <time_frame>between baseline and 6 months after goserelin discontinuation</time_frame>
    <description>Bone mineral density changes at the lumbar spine measured by dual-energy absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>femoral neck BMD</measure>
    <time_frame>between baseline and 6 months after goserelin initiation</time_frame>
    <description>Bone mineral density changes at the femoral neck measured by dual-energy absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>femoral neck BMD</measure>
    <time_frame>between baseline and 6 months after goserelin discontinuation</time_frame>
    <description>Bone mineral density changes at the femoral neck measured by dual-energy absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sclerostin</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>bone metabolism parameter measured in sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>periostin</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>bone metabolism parameter measured in sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irisin</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>myokine measured in sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follistatin</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>myokine measured in sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activin-A</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>myokine measured in sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>noggin</measure>
    <time_frame>0,3,6,12 months</time_frame>
    <description>BMP inhibitor measured in sera</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Endometriosis</condition>
  <condition>Bone Density</condition>
  <condition>Muscle</condition>
  <condition>Bone Metabolism</condition>
  <arm_group>
    <arm_group_label>Endometriosis Group</arm_group_label>
    <description>20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months</description>
    <arm_group_label>Endometriosis Group</arm_group_label>
    <other_name>GnRH analog</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal women with surgically verified endometriosis will receive goserelin 1
        injection per month for 6 months. Subsequently goserelin will be discontinued and patients
        will be monitored for another 6 months after menstrual restoration. Age- and BMI-matched
        premenopausal, health women will serve as controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Premenopausal women with surgically verified endometriosis

        Exclusion Criteria:

          1. Secondary osteoporosis

          2. diseases or conditions that could affect bone and/or muscle metabolism

          3. any medications that could affect bone and/or muscle metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Premenopausal women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanasios Anastasilakis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>424 General Military Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athanasios Anastasilakis, PhD</last_name>
    <phone>+302310381697</phone>
    <email>a.anastasilakis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polyzois Makras, PhD</last_name>
    <phone>+302107463603</phone>
    <email>pmakras@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>424 General Military Hospital</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Anastasilakis, PhD</last_name>
      <phone>+302310381697</phone>
      <email>a.anastasilakis@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stylianos Mandanas, MD</last_name>
      <phone>+302310381902</phone>
      <email>smandanas@yahoo.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Melis GB. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 1996 Apr;65(4):707-10.</citation>
    <PMID>8654625</PMID>
  </reference>
  <reference>
    <citation>Waibel-Treber S, Minne HW, Scharla SH, Bremen T, Ziegler R, Leyendecker G. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum Reprod. 1989 May;4(4):384-8.</citation>
    <PMID>2526152</PMID>
  </reference>
  <reference>
    <citation>Taga M, Minaguchi H. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand. 1996 Feb;75(2):162-5.</citation>
    <PMID>8604604</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>424 General Military Hospital</investigator_affiliation>
    <investigator_full_name>Athanasios D. Anastasilakis</investigator_full_name>
    <investigator_title>Consultant of endocrinology</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>myokines</keyword>
  <keyword>sclerotin</keyword>
  <keyword>periostin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After study results being accepted for publication they will be available for everyone that might ask for them</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

